BHC - Bausch Health Companies Inc.

NYSE - NYSE Delayed Price. Currency in USD
23.44
-0.17 (-0.72%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close23.61
Open23.61
Bid0.00 x 2200
Ask0.00 x 800
Day's Range23.13 - 23.72
52 Week Range17.20 - 28.45
Volume2,022,683
Avg. Volume3,978,093
Market Cap8.222B
Beta (3Y Monthly)2.11
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-11-10
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • CNW Group7 days ago

    Bausch + Lomb Announces U.S. Launch Of Ocuvite® Eye Performance Vitamins

    BRIDGEWATER, N.J. , July 9, 2019 /CNW/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced the U.S. launch of Ocuvite® Eye Performance vitamins, a nutritional supplement designed to meet the changing needs of consumers while further expanding the company's eye vitamin portfolio. "Today's modern, always-on world has evolved faster than our eyes – from the blue light of computer screens and cell phones to the increased UV exposure from the sun – which can have an impact on our eye health," said Joe Gordon , U.S. president, Bausch + Lomb.

  • PR Newswire8 days ago

    Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6

    LAVAL, Quebec , July 8, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter 2019 financial results on Tuesday, Aug. 6, 2019 . Bausch ...

  • CNW Group21 days ago

    Bausch Health To Reduce Debt By Additional $100 Million Using Cash Generated From Operations

    LAVAL, Quebec , June 25, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it put in notice to pay down an additional $100 million of its senior secured term loans this week, using cash generated from operations. After this payment, the Company will have eliminated all mandatory amortization for the first quarter of 2020. Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products.

  • PR Newswire21 days ago

    Bausch Health Announces U.S. Launch of DUOBRII™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis in Adults

    LAVAL, Quebec, June 25, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that DUOBRII™ (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, will be available commercially to health care professionals starting this week. Approved by the U.S. Food and Drug Administration on April 25, 2019, DUOBRII is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation. "The launch of DUOBRII marks the fifth innovative therapy that Ortho Dermatologics has brought forward within the last 30 months," said Bill Humphries, president, Ortho Dermatologics.

  • PR Newswire27 days ago

    Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses Now Available In the United States

    BRIDGEWATER, N.J., June 19, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced the U.S. launch of Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first and only multifocal toric lens available as a standard offering in the eye care professional's fit set. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision needs of patients with both astigmatism and presbyopia, combines the company's unique 3-Zone Progressive™ multifocal design with the stability of its OpticAlign® toric design to provide eye care professionals and their patients an advanced contact lens technology that offers the convenience of same-day fitting during the initial lens exam.

  • PR Newswire2 months ago

    Bausch Health Companies Announces Participation in Upcoming Investor Conferences

    LAVAL, Quebec , May 29, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that the Company will participate in two investor conferences in June. Paul S. Herendeen , executive ...

  • PR Newswire2 months ago

    Bausch Health Announces Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes

    LAVAL, Quebec, May 23, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today the results to date of its pending cash tender offers (collectively, the "Tender Offers," and each offer to purchase a series of notes individually, a "Tender Offer") to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of its outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement date for the Tender Offers on May 24, 2019 (the "Early Settlement Date"). The terms and conditions of the Tender Offers are described in an Offer to Purchase dated May 9, 2019 (as it may be amended or supplemented from time to time, the "Offer to Purchase") and the related Letter of Transmittal.

  • PR Newswire2 months ago

    Bausch Health Announces Pricing Of Private Offering Of Senior Notes

    LAVAL, Quebec, May 9, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced its previously announced offering of $750,000,000 aggregate principal amount of 7.000% senior notes due 2028 (the "2028 Notes") and $750,000,000 aggregate principal amount of 7.250% senior notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes"). The 2028 Notes will be sold to investors at a price of 100.00% of the principal amount thereof and the 2029 Notes will be sold to investors at a price of 100.00% of the principal amount thereof. Bausch Health intends to use the net proceeds from the offering of the Notes, along with cash on hand, to repurchase $1,500 million aggregate principal amount across the Company's outstanding 5.50% Senior Notes due 2023 (the "5.50% Notes") and 5.875% Senior Notes due 2023 (the "5.875% Notes" and, together with the 5.50% Notes, the "Existing Notes"), pursuant to its previously announced tender offers, and to pay related fees and expenses.

  • CNW Group2 months ago

    Bausch Health Commences Cash Tender Offers For Up To $1,500,000,000 Aggregate Principal Amount Of Outstanding Notes Of Certain Series

    LAVAL, Quebec , May 9, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today that it has commenced cash tender offers (collectively, the "Tender Offers," and each offer to purchase a series of notes individually, a "Tender Offer") to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of its outstanding notes listed in the table below (collectively, the "Notes"). The terms and conditions of the Tender Offers are described in an Offer to Purchase dated May 9, 2019 (as it may be amended or supplemented from time to time, the "Offer to Purchase") and the related Letter of Transmittal.

  • PR Newswire2 months ago

    Bausch Health Announces Launch Of Private Offering Of Senior Notes

    LAVAL, Quebec, May 9, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of $750,000,000 aggregate principal amount of senior notes due 2028 (the "2028 Notes") and $750,000,000 aggregate principal amount of senior notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes"). Bausch Health intends to use the net proceeds from the offering of the Notes, along with cash on hand, to repurchase $1,500 million aggregate principal amount across the Company's outstanding 5.50% Senior Notes due 2023 (the "5.50% Notes") and 5.875% Senior Notes due 2023 (the "5.875% Notes" and, together with the 5.50% Notes, the "Existing Notes") pursuant to tender offers announced today, and to pay related fees and expenses.

  • CNW Group2 months ago

    Bausch Health Companies Inc. Announces First-Quarter 2019 Results And Raises Full-Year Guidance

    Bausch Health Companies Inc. Announces First-Quarter 2019 Results And Raises Full-Year Guidance

  • PR Newswire3 months ago

    Bausch Health Issues Form 8K For 2019 Annual Meeting Of Shareholders Presentation

    LAVAL, Quebec , April 30, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") today announced Bausch Health Companies Inc. (the "Company") is providing ...

  • CNW Group3 months ago

    Bausch + Lomb Announces New Scientific Analyses Featuring Surgical And Pharmaceutical Products Will Be Presented During The Annual Meeting Of The American Society Of Cataract And Refractive Surgery

    Bausch + Lomb Announces New Scientific Analyses Featuring Surgical And Pharmaceutical Products Will Be Presented During The Annual Meeting Of The American Society Of Cataract And Refractive Surgery